GO:1901838 positive regulation of transcription of nucleolar large rRNA by RNA polymerase I

GO:1901838, positive regulation of transcription of nucleolar large rRNA by RNA polymerase I, is a Gene Ontology biological_process term that captures any process which activates or increases the frequency, rate or extent of transcription of nuclear large rRNA mediated by RNA polymerase I. In eukaryotic cells, the nucleolus is the site where RNA polymerase I (Pol I) transcribes the large ribosomal RNA precursor, a rate-limiting step for ribosome assembly and global protein synthesis. Because ribosome production is tightly coupled to cell growth, proliferation, and stress responses, the positive regulation of Pol I transcription is a central node in cellular physiology. Mechanistically, this term encompasses the recruitment and activation of Pol I at the ribosomal DNA (rDNA) promoter, the assembly of the pre-initiation complex, and the elongation of the large rRNA transcript. Upstream Binding Factor (UBF) is one of the best-characterized positive regulators in this process; its conditional inactivation in cells alters nucleolar architecture, reduces rRNA synthesis, and reveals epigenetic functions at rDNA loci. This makes GO:1901838 a critical term for researchers studying nucleolar biology, ribosome biogenesis, and growth control. For biomedical researchers, GO:1901838 provides a standardized way to annotate genes and pathways that drive rRNA transcription. It is particularly relevant in cancer biology, where increased Pol I activity supports the high biosynthetic demands of tumor cells, and in ribosomopathies, where defects in ribosome production lead to tissue-specific pathologies. Understanding the positive regulation of Pol I transcription therefore bridges molecular mechanism, disease, and therapeutic targeting.

In simple terms, GO:1901838 describes the set of processes that turn up or accelerate the transcription of the large ribosomal RNA in the nucleolus by RNA polymerase I. According to the QuickGO definition, it is any process that activates or increases the frequency, rate or extent of transcription of nuclear large rRNA mediated by RNA polymerase I. This term is a biological_process and includes synonyms such as activation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter and positive regulation of transcription of nuclear rRNA large Pol I transcript. It does not cover transcription by RNA polymerase II or III, nor does it describe the processing or modification of rRNA after it is made; it is specifically about positive regulation of the Pol I-driven synthesis of the large rRNA precursor.

GO:1901838 is important because the positive regulation of RNA polymerase I transcription sets the upper limit for ribosome production and therefore for protein synthesis capacity in growing cells. When this process is increased, cells can meet the biosynthetic demands of proliferation; when it is dysregulated, it contributes to diseases such as cancer and ribosomopathies. Because UBF and other positive regulators coordinate rDNA chromatin state and Pol I recruitment, this GO term provides a precise annotation for genes that control nucleolar output.

The following genes and proteins are established or strongly implicated in the positive regulation of nucleolar large rRNA transcription by RNA polymerase I, based on published literature.

The positive regulation of Pol I transcription is controlled by multiple signaling pathways and epigenetic mechanisms. Growth factor signaling through mTOR promotes ribosome biogenesis and supports Pol I activity. UBF acts as a key downstream effector, and its conditional inactivation demonstrates that it is required for maintaining rRNA synthesis and nucleolar structure. Tumor suppressors such as RB1 and TP53 restrain Pol I transcription, and their loss or mutation can lead to increased rRNA synthesis. Chromatin modifiers, including SIRT1, influence rDNA accessibility and thus the positive regulation of Pol I transcription. Together, these layers ensure that rRNA production matches cellular growth demands and stress conditions.

Many cancer cells exhibit elevated Pol I transcription to support rapid proliferation and high protein synthesis rates. Oncogenes such as MYC stimulate Pol I activity, while tumor suppressors such as RB1 and TP53 normally restrain it. Positive regulators like UBF are therefore considered potential therapeutic targets, and their inhibition can reduce rRNA synthesis and tumor cell growth.

Ribosomopathies are disorders caused by defects in ribosome biogenesis, often involving mutations in Pol I subunits or assembly factors. Impaired positive regulation of Pol I transcription can lead to insufficient rRNA production, nucleolar stress, and tissue-specific phenotypes such as craniofacial abnormalities and bone marrow failure. Studying UBF and associated factors in model systems helps clarify how Pol I dysfunction contributes to these diseases.

Nucleolar stress occurs when rRNA synthesis is disrupted, leading to p53 activation and cell cycle arrest. Chronic nucleolar stress has been linked to neurodegenerative conditions, although the exact mechanisms remain under investigation. Positive regulation of Pol I transcription is therefore relevant to neuronal survival and stress responses.

Because ribosome production is energetically expensive, its positive regulation is tightly coupled to nutrient sensing pathways such as mTOR. Dysregulation of Pol I transcription has been implicated in metabolic disorders and aging, where altered protein synthesis capacity affects cellular homeostasis. Targeting this process may offer strategies to modulate aging-related decline.

Pol I transcription can be measured using nuclear run-on assays, rRNA precursor quantification by RT-qPCR, and metabolic labeling of newly synthesized RNA. These methods directly assess the rate of large rRNA synthesis and are used to validate positive regulators such as UBF.

ChIP and ChIP-seq for Pol I subunits, UBF, and histone modifications reveal occupancy at rDNA loci and changes in chromatin state. These approaches help define how positive regulators are recruited to rDNA and how their loss affects promoter accessibility.

RNA-seq can quantify rRNA precursors and processing intermediates, while Ribo-seq measures global translation efficiency. Combining these methods links positive regulation of Pol I transcription to downstream protein synthesis capacity.

Fluorescence microscopy of nucleolar markers such as fibrillarin and nucleolin assesses nucleolar structure and activity. Proteomics of nucleolar fractions can identify changes in Pol I complex composition upon genetic perturbation.

Researchers studying positive regulation of transcription of nucleolar large rRNA by RNA polymerase I-related genes often need to determine whether a candidate gene is causally involved in rRNA synthesis, nucleolar structure, or disease phenotypes. Rigorous causal inference requires well-controlled genetic models that can isolate the contribution of a single gene or mutation. EDITGENE provides a comprehensive suite of CRISPR-based cell model services to support such studies.

GO:1901838 provides a precise ontological framework for the positive regulation of RNA polymerase I-mediated transcription of the nucleolar large rRNA. This process is fundamental to ribosome biogenesis, cell growth, and protein synthesis, and its dysregulation is implicated in cancer, ribosomopathies, and other diseases. Key regulators such as UBF have been functionally validated using conditional knockout and other genetic models. Continued research using CRISPR-engineered cell models, transcriptomics, proteomics, and imaging will further clarify the mechanisms and therapeutic potential of targeting this pathway.